13F filing recap · Q1 2016

What did Mairs & Power buy in Q1 2016?

Reported stock-position changes between this filing and the previous one. US-listed stocks across every Mairs & Power account, including accounts that belong to no fund below.

Stock value

$7.04B

Positions

188

Estimated turnover

8.0%

Turnover is a proxy: verified trade-origin share changes valued at period-end and divided by average reported stock value. SEC holdings reports do not disclose execution dates or prices. Corporate actions and unreconciled activity are excluded.

New positions

GWBGreat Western Bancorp, Inc.$15.81Mreported value+579.6K shares EMCIEmc Insurance Group Inc.$2.03Mreported value+79.0K shares RGRSturm, Ruger & Company, Inc.$219.0Kreported value+3.2K shares RTNRaytheon Company$205.0Kreported value+1.7K shares TXNTexas Instruments Incorporated$201.0Kreported value+3.5K shares

Increased positions

MMM3m Company$305.13Mreported value+13.6K shares+0.7%ECLEcolab Inc.$276.25Mreported value+63.6K shares+2.6%USBUS Bancorp$268.89Mreported value+334.2K shares+5.3%JNJJohnson & Johnson$236.44Mreported value+905 shares

Reduced positions

VALValspar Corporation$251.19Mreported value-515.6K shares-18.0%HONHoneywell International Inc$242.13Mreported value-63.1K shares-2.8%GGGGraco Inc.$239.29Mreported value-354 shares-0.0%BMSBemis Company Inc$233.14Mreported value-130.8K shares

Exited positions

XLETechnology Select Sector SPDR Fund$377.0Kprior reported value-6.3K shares-100.0%CELGCelgene Corporation$321.0Kprior reported value-2.7K shares-100.0%METAMeta Platforms, Inc.$268.0Kprior reported value-2.6K shares-100.0%ALNYAlnylam Pharmaceuticals, Inc.$217.0Kprior reported value